SAN DIEGO, Jan. 29, 2015 /PRNewswire/ -- Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics, today announced that it will be presenting at the 17th Annual BIO CEO and Investor Conference in New York at the Waldorf Astoria. Dr. Hubert Chen, chief medical officer of Pfenex, will provide an overview of the company's development programs and business strategy on February 9th at 10:00 a.m. ET. A live audio webcast and archive of the presentation will be available in the Investor Relations section of the Pfenex website at www.pfenex.com.
Pfenex has used, and intends to continue to use, its Investor Relations website (http://pfenex.investorroom.com), as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. For more information, visit (http://pfenex.investorroom.com).
About Pfenex Inc.
Pfenex Inc. is a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics and high-value and difficult to manufacture proteins. The company's lead product candidate is PF582, a biosimilar candidate to Lucentis (ranibizumab), for the potential treatment of patients with retinal diseases. Pfenex has leveraged its Pfenex Expression Technology® platform to build a pipeline of product candidates and preclinical products under development including other biosimilars, as well as vaccines, generics and next generation biologics.
SOURCE Pfenex Inc.